SK bioscience、IDT Biologika 與 Vaxxas 入選歐盟資助的下一代流感疫苗開發計畫
2026年3月12日
2 min read
規範來源South Korea
仅摘要
核心变化
SK bioscience、IDT Biologika 和 Vaxxas 獲歐盟選中參與次世代流感疫苗開發計畫，此舉標誌著疫苗創新領域一項新的合作努力。
Sigvera Intelligence
信源等级:发现
Source Report
SK bioscience 與合作夥伴 IDT Biologika 和 Vaxxas，獲選參與一項由歐盟資助的下一代流感疫苗開發計畫。
Industry Context
健康科技与生物技术
Where this signal fits in the broader landscape.
115 条行业信号合作
Source Verification
Verified from official source
Publisher—
發佈日期Mar 12, 2026
來源分類Verified Canonical
信号时间线
首次报道Mar 12, 2026
索引时间Mar 12, 2026
发布时间Mar 12, 2026
https://www.prnewswire.com/news-releases/sk-bioscience-idt-biologika-and-vaxxas-selected-for-next-generation-influenza-vaccine-development-financed-by-the-european-union-302697969.html
Read Full SourceGet cross-language signal intelligence
Get curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
My Notes
Sign in to save notes on signals.
登录